Results 31 to 40 of about 1,702,455 (203)

Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?

open access: yes, 2022
20.500.12530/87857It is not clear if platelet responses are sustained after thrombopoietin receptor agonist (ar-TPO) withdrawal in paediatric patients.
Rubén Berrueco   +19 more
core   +1 more source

Use of Thrombopoietin Receptor Agonists in Pregnancy

open access: yesHematology/Oncology and Stem Cell Therapy, 2022
The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a shift in treatment modalities.
Jude, Howaidi   +4 more
openaire   +2 more sources

A marine sponge-derived lectin reveals hidden pathway for thrombopoietin receptor activation

open access: yes, 2022
N-glycan-mediated activation of the thrombopoietin receptor (MPL) under pathological conditions has been implicated in myeloproliferative neoplasms induced by mutant calreticulin, which forms an endogenous receptor-agonist complex that traffics to the ...
Nakajima, Hiroya   +18 more
core   +1 more source

Clinical Indications for Thrombopoietin and Thrombopoietin-Receptor Agonists [PDF]

open access: yesTransfusion Medicine and Hemotherapy, 2013
Thrombocytopenia is a common hematologic disorder. Stimulation of thrombopoiesis may reduce the risk for thrombocytopenia-induced bleeding, prevent severe thrombocytopenia, and reduce the need for platelet transfusion. The key cytokine is thrombopoietin (TPO).
openaire   +2 more sources

Development of thrombopoietin receptor agonists for clinical use [PDF]

open access: yesJournal of Thrombosis and Haemostasis, 2009
Thrombopoietin (TPO) is an essential hematopoietic cytokine for megakaryopoiesis. In 2002, we demonstrated that pegylated-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts in patients with chronic immune thrombocytopenic purpura (ITP) in a Phase I/II clinical trial.
Y, Ikeda, Y, Miyakawa
openaire   +2 more sources

Biochemical pharmacology of the positive allosteric modulation of the GABAb receptor "in Vitro" and "in Vivo" [PDF]

open access: yes, 2007
Allosteric modulators of G-protein coupled receptors (GPCRs) interact with binding sites on the receptor molecule that are topographically distinct from the classic orthosteric site.
Gjoni, Tina
core   +1 more source

A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience [PDF]

open access: yes, 2019
Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP)
Guven Cetin   +200 more
core   +1 more source

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation [PDF]

open access: yes, 2016
Somatic mutations in calreticulin (CALR) are present in approximately 40% of patients with myeloproliferative neoplasms (MPN), but the mechanism by which mutant CALR is oncogenic remains unclear.
Schneider, RK   +31 more
core   +1 more source

Safety, tolerance, pharmacokinetic and pharmacodynamic properties of thrombopoietin mimetic peptide for injection in Chinese healthy volunteers: a randomized, placebo-controlled, double-blind study

open access: yesPlatelets, 2022
The thrombopoietin mimetic peptide for injection is a second-generation thrombopoietin receptor agonist (TPO-RA) used in the treatment of patients with immune thrombocytopenia.
Xiao-Yan Sheng   +6 more
doaj   +1 more source

Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report

open access: yesJTO Clinical and Research Reports, 2022
A 69-year-old man presented with a pulmonary opacity at a regular medical check-up. He had been exposed to asbestos in a chemical fiber manufacturing setting.
Takaaki Tanaka, MD   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy